Pure Global: USA's 510(k) Cybersecurity Ambush for MedTech Firms

Last week, the U.S. FDA began strict enforcement of new cybersecurity rules for medical devices, catching many global manufacturers by surprise. This sudden shift requires a complete software bill of materials (SBOM) and a proactive security plan, leading to submission rejections and significant market delays for unprepared companies. This episode of MedTech Global Insights dives into the immediate impact of the FDA's new stance. We break down what this means for device makers, from startups to enterprise leaders, and explore the strategic adjustments necessary to navigate this new, complex regulatory landscape and avoid costly mistakes at the finish line. **Key Takeaways:** * What are the three most common deficiencies in a cybersecurity submission that lead to an immediate FDA rejection? * How can you create a Software Bill of Materials (SBOM) for a legacy device without rebuilding it from scratch? * Is your post-market surveillance plan truly proactive, or just a reactive promise? * How does the FDA's cybersecurity enforcement compare to upcoming regulations in the EU? * What tools and processes must be integrated into your Quality Management System to ensure compliance? * Can you leverage your existing technical file to meet these new, demanding requirements? * What are the unwritten expectations from FDA reviewers when they assess your cybersecurity file? Contact us at [email protected] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.